Diabetes-Technologie: Stand der Dinge

Im Rahmen einer optimalen Betreuung von Patienten mit Diabetes ist die Diabetes-Technologie (DT) heute eine tragende Säule. Im Fokus stehen vor allem Glukosemonitoring, Insulinapplikation und digitale Optionen. Dieser Beitrag stellt die verschiedenen DT-Themen kurz dar – auch in Hinsicht auf anstehende Aufgaben. Im Anschluss werden die diesbezüglichen Aktivitäten der Arbeitsgemeinschaft für Diabetes & Technologie (AGDT) und der DDG vorgestellt.

Abstract

In the last decades diabetes technology has developed into an integer part of diabetes therapy. A number of different technologies, most of them are also related to digitalization, are summarized under this heading: techniques that enable a more accurate and reliable diagnostic approach, i. e. glucose measurement for both, follow-up and diabetes diagnosis. Self-monitoring of capillary blood glucose samples is still a cornerstone of diabetes therapy of most patients with diabetes. It is impressive to see which level of measurement accuracy is possible with modern devices. With a smarter handling of the glucose information collected, i. e. better translation into therapeutic action, improvements in patientʼs overall glucose control and well-being can be achieved. Technological advancements also helped to improve insulin pens and insulin pumps in the last years considerably, especially the development of thin and short needles. Bringing the glucose information with the therapeutic options available in a smart way enables construction of systems that automatically adjust insulin dosing to the individual needs and situation. Artificial pancreas systems will be used most probably by a considerable part of patients with diabetes, depending mainly on the costs involved. Digitalization will massively change the way patients are treated in the future, many decisions will not be made by the diabetologist and his team, but by smart algorithms. Such developments are associated with a number of aspects like data privacy that require careful handling and attention by diabetes medical associations. In summary, diabetes technology represents already an important pillar of diabetes therapy that most probably will gain an even bigger role in the future.

Schlüsselwörter

Diabetes-Technologie - kontinuierliches Glukosemonitoring - Insulin-Pens - Insulinpumpen - Digitalisierung

Key words

diabetes technology - continuous glucose monitoring - insulin pens - insulin pumps - digitalization

• Literatur

• 1 Bergenstal RM, Garg S, Weinzimer SA. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016; 316: 1407-1408
• 2 Heinemann L, Deiss D, Siegmund T. et al. Praxisempfehlung der DDG: Glukosemessung und -kontrolle bei Patienten mit Typ-1- oder Typ-2-Diabetes. Diabetologie 2017; 12 (Suppl. 02) S242-S262
• 3 Nauck M, Petermann A, Müller-Wieland D. et al. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie 2017; 12 (Suppl. 02) S94-S100
• 4 Heinemann L, Dänschel I, Dänschel W. et al. Integrated personalized diabetes management (iPDM) in patients with insulin-treated T2DM: Results of the PDM-ProValue study program, IDF Kongress 2017, Abu Dhabi, presentation number P-1120.
• 5 Gehr B, Holder M, Kulzer B. et al. SPECTRUM. J Diabetes Sci Technol 2017; 11: 284-289
• 6 Heinemann L, Deiss D, Karch A. et al. CGM und berufliche Tätigkeiten: Neue Realitäten!. Diabetologie, Stoffwechsel und Herz 2018; 27: 117-121
• 7 Heinemann L, Kamann S. Adhesives used for diabetes medical devices: a neglected risk with serious consequences?. J Diabetes Sci Technol 2016; 10: 1211-1215
• 8 Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805
• 9 Heinemann L, Freckmann G, Ehrmann D. et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicenter, randomised controlled trial. Lancet 2018; 391: 1367-1377
• 10 Beck RW, Riddlesworth T, Ruedy K. et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317: 371-378
• 11 Lind M, Polonsky W, Hirsch IB. et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. JAMA 2017; 317: 379-387
• 12 Kropff J, Choudhary P, Neupane S. et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care 2017; 40: 63-68
• 13 Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012; 6: 728-742
• 14 Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 2012; 6: 954-964
• 15 Barnard KD, Venkat MV, Close K. et al. PsychDT Working Group: Report Psychosocial Aspects of Artificial Pancreas Systems. J Diabetes Sci Technol 2015; 9: 925-928
• 16 Barnard KD, Wysocki T, Thabit H. et al. Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabet Med 2015; 32: 601-608
• 17 Heinemann L, Fleming GA, Petrie JR. et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 2015; 58: 862-870
• 18 Petrie JR, Peters AL, Bergenstal RM. et al. Improving the clinical value and utility of CGM systems: issues and recommendations: A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 2017; 60: 2319-2328
• 19 Kubiak T, Mann CG, Heinemann L. Kontinuierliches Glukosemonitoring im Erleben des individuellen Patienten. Diabetologie 2015; 10: 29-35
• 20 Heinemann L, Ickrath M. Digitalisierung und Diabetestechnologie. Diabetologe 2016; 12: 533-537
• 21 Heinemann L, Ickrath M. Digitalisierung: Visionen für eine Diabetologie der Zukunft. Dtsch Arztebl 2017; 114: 26
• 22 Kaltheuner M, Droßel D, Heinemann L. DiaDigital – Unterstützung von Patienten und Diabetologen bei der Nutzung von Apps. Diabetologe 2016; 12: 538-549
• 23 Kempf K, Altpeter B, Berger J. et al. Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: a randomized controlled trial. Diabetes Care 2017; 40: 863-871